1. Ashmarin IP, Nezavibatko VN, Myasoedov NF, Kamensky AA, Grivennikov IA, Ponomareva-Stepnaya MA, Andreeva LA, Kaplan AY, Koshelev VB, Ryasina TV. Nootropic analogue of adrenocorticotropin 4-10-Semax: (the experience of design and investigation over 15 years). Zh. Vyssh. Nervn. Deyat. 1997;47(2):429-430. Russian.
2. V’unova TV, Shevchenko KV, Shevchenko VP, Bobrov MYu, Bezuglov VV, Myasoedov NF. Binding of Regulatory Neuropeptide [3H] Semax, Labeled in Terminal Pro, to Plasma Membranes of the Rat Forebrain. Neirokhimiya. 2006;23(1):57-62. Russian.
3. Gusev EI, Skvortsova VI, Myasoedov NF, Nezavibat’ko VN, Zhuravleva EYu, Vanichkin AV. Effectiveness of Semax in acute period of hemispheric ischemic stroke (clinical and electrophysiological study). Zh. Nevrol. Psikhiatr. 1997;96(6):26-54. Russian.
4. Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh. Nevrol. Psikhiatr. 2005;105(2):35-40.
5. Shuvaev AN, Salmin VV, Kuvacheva NV, Pozhilenkova EA, Salmina AB. Modern tendencies in the development of the patchclamp technique: new opportunities for neuropharmacology and neurobiology. Annaly Klin. Eksp. Nevrol. 2015;9(4):54-58. Russian.